Revolution medicines to participate in the guggenheim securities smid cap biotech conference

Redwood city, calif., jan. 29, 2025 (globe newswire) -- revolution medicines, inc. (nasdaq: rvmd), a clinical-stage oncology company developing novel targeted therapies for patients with ras-addicted cancers, today announced that mark a. goldsmith, m.d., ph.d., the company's chief executive officer and chairman, will participate in a fireside chat as part of the guggenheim securities smid cap biotech conference on wednesday, february 5, 2025, at 10:30 a.m. et.
SMID Ratings Summary
SMID Quant Ranking